Correction to: Pharm Res (2018) 35: 138
There was a miscalculation of coproporphyrin I AUC0-24h in the published article (Volume 35, Number 7). After the correction of AUC0-24h, AUC ratio and R-square were re-calculated. Then, following corrections were made in the abstract, the body, Fig. 3, Fig. 4 and Table 2 in this article. The interpretation of data in this article was not influenced.
The corrected sentences are below.
line 20: coproporphyrin I (r2 = 0.78).
line 23: (r2 = 0.48–0.70).
Effect of Rifampicin on the Plasma Concentrations of Coproporphyrin I.
line 4: 2.3- and 3.5-times higher.
Correlations between the AUC0–24h of Endogenous OATP1B Substrates, and of these with the AUC0–24h of Atorvastatin.
line 6: coproporphyrin I (r2 = 0.78).
line 8: atorvastatin (r2 of 0.65, 0.70 and 0.48, respectively).
The corrected Figures and Table appears below.
Table 2, line 6 Coproporphyrin I.
|Probe drug||Control||+P||+RIF300||Fold changea||+RIF600||Fold changea|
|Coproporphyrin I||nd||16.8 ± 1.6||38.1 ± 2.7**||2.3 ± 0.1||57.8 ± 3.8**,††||3.5 ± 0.1|
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s11095-018-2416-3
About this article
Cite this article
Takehara, I., Yoshikado, T., Ishigame, K. et al. Correction to: Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers. Pharm Res 36, 55 (2019). https://doi.org/10.1007/s11095-019-2585-8